Previous 10 | Next 10 |
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older 1 ZTALMY significantly reduced major motor seizure frequency in CDD patients in the pivotal Marigold trial Rare Pediatric Disea...
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q4 earnings results on Monday, March 21st, before market open. The consensus EPS Estimate is -$0.74 (-34.5% Y/Y) and the consensus Revenue Estimate is $3.5M (+127.3% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward r...
AXU, MRNS, PDD For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Marinus has a March PDUFA date - when the FDA will rule on whether to approve an oral formulation of Ganaxolone in CDKL5 Deficiency Disorder ("CDD"). Ganaxolone is Marinus' lead and only product and it has a long and checkered history - having failed in depression, it may succeed in e...
Marinus (MRNS -20.5%) has recorded the biggest intraday loss since March 2020 on Wednesday to approach a 52-week low after the clinical-stage pharma company announced delays for several clinical programs involving an IV formulation of its only product candidate, ganaxolone. The company a...
Gainers: Revelation Biosciences REVB +29%. Mainz Biomed MYNZ +9%. Relmada Therapeutics (NASDAQ:RLMD) +9%. Panbela Therapeutics (NASDAQ:PBLA) +7%. Pyxis Oncology (NASDAQ:PYXS) +4%. Losers: Kodiak Sciences KOD -78%. Ocugen OCGN -20%. R...
The clinical stage pharmaceutical company, Marinus Pharma (NASDAQ:MRNS) has lost ~18% in the post market Tuesday after Radnor, Pennsylvania-based firm announced delays to several clinical studies citing the impact of COVID-19 and Omicron variant of the virus. In addition to Omicron ...
RAISE trial delayed due to impacts from COVID-19 variant and recent interruption in clinical supply material Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today a...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ende...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...